The novel MAO-B inhibitors developed in this study are expected to overcome the limitations of existing drugs, such as improved efficacy, reduced side effects, and enhanced selectivity, and provide new options for the treatment of neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Here, MAOB is linked to early-onset autosomal dominant Alzheimer disease.